Biotech Values

[mcbio]

We maintain our Buy rating and $48 PO on KPTI shares given our view that Selinexor’s broad applicability across multiple indications beyond NHL, thus far benign safety profile and large phase 1 study (300+ patients) positions the company well relative to other early stage oncology companies.

Uh, shares closed Friday at $47 and change. Guess I shouldn't bother. ; )